Arcus Biosciences Management
Management criteria checks 2/4
Arcus Biosciences' CEO is Terry Rosen, appointed in May 2015, has a tenure of 9.08 years. total yearly compensation is $10.12M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $4.56M. The average tenure of the management team and the board of directors is 3.8 years and 4.3 years respectively.
Key information
Terry Rosen
Chief executive officer
US$10.1m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 9.1yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31
Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Jan 07Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically
Nov 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$231m |
| Dec 31 2023 | US$10m | US$650k | -US$307m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$287m |
| Mar 31 2023 | n/a | n/a | -US$279m |
| Dec 31 2022 | US$9m | US$350k | -US$267m |
| Sep 30 2022 | n/a | n/a | US$80m |
| Jun 30 2022 | n/a | n/a | US$67m |
| Mar 31 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$9m | US$367k | US$53m |
| Sep 30 2021 | n/a | n/a | -US$278m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$168m |
| Dec 31 2020 | US$6m | US$326k | -US$123m |
| Sep 30 2020 | n/a | n/a | -US$88m |
| Jun 30 2020 | n/a | n/a | -US$112m |
| Mar 31 2020 | n/a | n/a | -US$95m |
| Dec 31 2019 | US$2m | US$340k | -US$85m |
| Sep 30 2019 | n/a | n/a | -US$80m |
| Jun 30 2019 | n/a | n/a | -US$69m |
| Mar 31 2019 | n/a | n/a | -US$54m |
| Dec 31 2018 | US$1m | US$295k | -US$50m |
| Sep 30 2018 | n/a | n/a | -US$51m |
| Jun 30 2018 | n/a | n/a | -US$63m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$427k | US$315k | -US$53m |
Compensation vs Market: Terry's total compensation ($USD10.12M) is above average for companies of similar size in the US market ($USD5.66M).
Compensation vs Earnings: Terry's compensation has increased whilst the company is unprofitable.
CEO
Terry Rosen (64 yo)
9.1yrs
Tenure
US$10,120,945
Compensation
Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.1yrs | US$10.12m | 0.31% $ 4.6m | |
| Co- Founder & President | 9.1yrs | US$4.75m | 1.56% $ 22.7m | |
| Principal Financial Officer & CFO | 3.8yrs | US$3.59m | 0.017% $ 247.1k | |
| Chief Operating Officer | 3.7yrs | US$4.74m | 0.028% $ 404.2k | |
| Chief Medical Officer | 1.8yrs | US$3.69m | 0.015% $ 220.9k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| VP of Finance & Principal Accounting Officer | 1.3yrs | no data | 0.0032% $ 47.3k | |
| Chief Scientific Officer | 3.4yrs | no data | no data | |
| General Counsel & Corporate Secretary | 5.8yrs | US$2.92m | 0.047% $ 685.4k | |
| Vice President of Corporate Communications | no data | no data | no data | |
| Senior Vice President of Human Resources & Operations | no data | no data | no data | |
| Chief Commercial Officer | 5yrs | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: RCUS's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.2yrs | US$10.12m | 0.31% $ 4.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Lead Independent Director | 9.1yrs | US$503.21k | 0.16% $ 2.3m | |
| Independent Director | 6.8yrs | US$479.08k | 0.16% $ 2.4m | |
| Independent Director | 3.5yrs | US$455.83k | 0.023% $ 334.6k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.5yrs | US$455.83k | 0.019% $ 270.2k | |
| Independent Director & Member of Scientific Advisory Board | 4.1yrs | US$500.83k | 0.054% $ 787.5k | |
| Independent Director & Member of Scientific Advisory Board | 9.4yrs | US$470.83k | 0.034% $ 487.8k | |
| Director | 3.9yrs | no data | no data | |
| Independent Director | 2.8yrs | US$450.83k | 0.015% $ 224.4k | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: RCUS's board of directors are considered experienced (4.3 years average tenure).